key: cord-0967415-sg351yj2
authors: Malik, Prerna; Jain, Sonika; Jain, Pankaj; Kumawat, Jyoti; Dwivedi, Jaya; Kishore, Dharma
title: A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS‐CoV‐2
date: 2022-01-17
journal: Arch Pharm (Weinheim)
DOI: 10.1002/ardp.202100382
sha: f05c34e383ae1e3f5455362faff1a615a6b5e62a
doc_id: 967415
cord_uid: sg351yj2

The outbreak of the coronavirus pandemic COVID‐19 created by its severe acute respiratory syndrome corona virus‐2 (SARS‐CoV‐2) variant, known for producing a very severe acute respiratory syndrome, has created an unprecedented situation by its continual assault around the world. The crisis caused by the SARS‐CoV‐2 variant has been a global challenge, calling to mitigate this unprecedented pandemic that has engulfed the whole world. Since the outbreak and spread of COVID‐19, many researchers globally have been grappling to find new clinically trialed active drugs with anti‐COVID‐19 activity, from antimalarial drugs to JAK inhibitors, antiviral drugs, immune suppressants, and so forth. This article presents a brief discussion on the activity and synthesis of some active molecules such as favipiravir, hydroxychloroquine, pirfenidone, remdesivir, lopinavir, camostat, chloroquine, baricitinib, molnupiravir, and so forth, which are under trial.

In this context, a recent announcement from the United States through Anthony Fauci (the Chief Medical Advisor to US President) is worth reporting. It states that the US government is planning to take another major medical step to beat the pandemic, putting in $3.2 billion to develop "antiviral pills" to treat COVID-19 infection.

Oral therapies will be easier to produce, transport, store and administer. It could be taken at home easily during the course of the disease and therefore would be a powerful tool for battling the pandemic at the early stages and in saving lives.

The US Department of Health and Human Services revealed that 19 therapeutic agents have already been prioritized for testing in rigorous trials for outpatients and inpatients with COVID-19 ( Figure 2 ). Availability of Food and Drug Administration (FDA)-authorized "antiviral pills" through these efforts would be a major breakthrough in the ongoing efforts to combat A review of the literature on the drugs under trial reveals that the following drugs can inhibit the key components of the coronavirus infection ( Figure 3 ).

The coronavirus first binds or attaches to the ACE2 (angiotensinconverting enzyme) receptors that are present on the numosites.

When it binds to the ACE2 receptors, there is a change in the S-glycoprotein of the coronavirus; as a result, there is a cleavage or release of the fragments of S-proteins by the transmembrane protein of the host. As a result, the virus enters the cell through the early and late endosomes. Inside the cytoplasm, there is another protease, cathepsin-l, which further cleaves the S-protein at low pH, and there is a fusion of the viral envelope with the phospholipid membrane of the endosomes. After this fusion, there is a release of the viral genome in the cytoplasm. The second step is the release of the viral genome. The viral genome is released into the cytoplasm, after which a positive-strand RNA genome is converted into a negative-strand RNA genome, which is used as signal for for messenger RNA synthesis. Ribosomes are the host and they promote the synthesis and replication of the viral genome; also, they promote the synthesis of the non- Table 1 .

There are many other established drug molecules that are used alone or in combination that may also prove to be effective for COVID-19 therapy. This review focuses on these drugs (Figures 1   and 2 and Table 2 ) in terms of their activity and synthesis.

CQ, which is an antimalarial drug, was first discovered in 1934 at Bayer laboratories by Hans Andersag et al., [6] who named it Resochin.

CQ exerts an important effect that can help to deter or slow down the spread of SARS-CoV-2 infection. The medication could prevent the virus from infecting cells. [7] Coronaviruses use the ACE2 receptors to gain access to the cell. The compound has been shown to interact with ACE2 glycosylation. [8] This can affect the productivity of spike protein-ACE2 binding and inhibit entry of the virus into the cells. (7) The first description of the synthesis of CQ was provided by Andersag in 1934, and involved the condensation of 3-chloroaniline (1) with diethyl-2-oxosuccinate (2), yielding diethyl (E)-2-[ (3-chlorophenyl) imino]succinate (3) . Product 3 underwent saponification in the presence of liquid paraffin at 250°C to afford ethyl 7-chloro-4hydroxyquinoline-2-carboxylate (4); decarboxylation of 4 yielded 7-chloroquinolin-4-ol (5) . CQ (7) was obtained on chlorination of 5, followed by amination of the resulting 4,7-dichloroquinoline (6) (Scheme 1). CQ was also obtained by nucleophilic substitution of 4,7dichloroquinoline (6) with 2-amino-5-(diethylamino)pentane (8) at 130-155°C using phenol as a solvent [9] as shown in Scheme 2.

Price and Roberts [10] described the synthesis of 4,7dichloroquinoline (6), which is a key ingredient for the synthesis of CQ as demonstrated in Scheme 3. Schiff base (diethyl (Z)-2-[(phenylimino)methyl)malonate] (11) was prepared by reaction with m-chloroaniline (1) and ethoxy methyl enemalonic ester (10) at reflux temperature as shown in Scheme 3.

A new route to the synthesis of 4,7-dichloroquinoline (6) was described by Guy et al. [11] in 2004, as shown in Scheme 4. Instead of F I G U R E 2 Severe acute respiratory syndrome corona virus-2 multiplication stages inside the host cell MALIK ET AL. using ethoxymethylenemalonic ester, they used Meldrum's acid (15) . [12] Meldrum's acid regent has the considerable advantage of producing 4,7-dichloroquinoline in three steps instead of five.

Surrey and Hammer [13] described the synthesis of 4,7dichloroquinoline (6) using m-chloroaniline (1) and diethyl ester of oxaloacetic acid (17) . 4,7-Dichloroquinoline was prepared by cyclocondensation of 18, followed by hydrolysis and decarboxylation of 19 resulted 5 which on chlorination yielded 4,7-dichloroquinoline (Scheme 5).

Oral medications like HCQ and CQ have long been used to treat malaria and chronic inflammatory diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). [14] Though HCQ, a racemic combination, was found to be effective and was considered the first-line treatment for SLE and COVID-19 victims, HCQ and CQ are well-tolerated medications that have been widely investigated in individuals with SLE and malaria. Both compounds, on the contrary, have severe side effects such as QTc prolongation, hypoglycaemia, retinopathy, and neuropsychiatric effects. [15] 3.2.1 | Synthesis of HCQ (24) Sterling-Winthrop discovered the first method for the synthesis of Further, an improved route was proposed for the synthesis of HCQ (24) from 5-iodopentan-2-one, which was, in turn, obtained from 25 as shown in Scheme 7. When 26 was refluxed with 2-(ethylamino) ethan-1-ol (21) in tetrahydrofuran (THF) at its boiling point using potassium carbonate as a base, it afforded 5-[ethyl (2-hydroxyethyl) amino]pentan-2-one (27) . 2-[(4-Aminopentyl)(ethyl)amino]ethan-1-ol was obtained via the catalytic reduction of 5-[ethyl (2-hydroxyethyl) amino]pentan-2-one oxime (28) . HCQ (24) was obtained on nucleophilic substitution of 6 with 29 in the presence of triethylamine.

Yu et al. [17] pioneered the continuous flow mechanism of synthesizing HCQ (24) by dissolving 4,7-dichloroquinoline (6) and 5-(Nethyl-N-2-hydroxyethylamino)-2-pentylamine (30) in ethanol and then treatment with a solution of potassium carbonate and triethylamine at a high temperature. This process yielded HCQ (24) after purification with silica chromatography.

A simple method for the preparation of HCQ (24) in better yield was described by Kumar et al. [18] in 2003. They used an equimolar quantity of sodium hydroxide and a catalytic amount of sodium iodide at a higher temperature for condensation of 5-(N-ethyl-N-2hydroxyethylamino)-2-pentylamine (30) and 4,7-dichloroquinoline (6) to afford HCQ (24) as shown in Scheme 8.

Lopinavir (LPV) (Scheme 9) is an antiviral drug (protease inhibitor) used in HIV prevalence treatment and prevention in tandem with ritonavir (booster). In vitro testing of lopinavir's ability to inhibit the SARS-CoV main protease (3CLpro) was performed. No studies have been done on the effectiveness of lopinavir as antiviral agents in the treatment of SARS-CoV. [19] 3.3.1 | Synthesis of lopinavir In 1999 and 2000, Abbott laboratories (which are now Abbvie) described the formation of lopinavir in a patent and in two publications. [20] The first step included tribenzylation of L-phenylalanine (35) with benzyl chloride to give benzyl dibenzyl-L-phenylalaninate (36) .

The acetonitrile anion was derived from acetonitrile treatment with a base, sodium amide was then added to the benzyl ether in the next step, and the resulting nitrile (37) was then treated with benzyl magnesium chloride in a one-pot reaction in MTBE to give 38.

The trifluoroacetic acid (TFA) complex of enaminone (38) was reduced with NaBH 4 to give amino alcohol (33) (Scheme 10).

In the next step, L-valine (40) was converted into (phenoxycarbonyl)-L-valine (41) [21] (Scheme 11) on its treatment with phenyl chloroformate in the presence of lithium chloride, which allowed the reaction to take place at a very low temperature.

Neutral ammonia was also used to avoid gumming and emulsion formation. Treatment of (phenoxy-carbonyl)-L-valine (41) Scheme 12 demonstrates the final step to achieve lopinavir. [22] (S)-3-Methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl) butanoyl chloride (43) was coupled with an amine in EtOAc/dimethylformamide (DMF) at 30°C to give 44, which was followed by debenzylation in the presence of activated palladium and ammonium formate at 50°C to give amine (45) . The diastereomeric purity was achieved by crystallizing the salt with L-pyroglutamic acid (PGA) in 1,4-dioxane, which yielded PGA (45) in 74% yield more than 98.5% purity. The final amide coupling of [24] dystrophic epidermolysis, [25] and exocrine pancreatic enzyme inhibition [26, 27] have all been treated with camostat mesylate. (57) 4-Hydroxyphenylacetic acid (53) 

Remdesivir has been considered as a potential therapeutic for COVID-19 because of its broad-spectrum in vitro activity against several coronavirus strains, which also includes SARS-CoV-2. [28, 29] Remdesivir is administered as an intravenous injection, and its safety The synthesis of remdesivir was initiated by the scientists of the Gilead Biopharmaceutical Company in 2016. [31, 32] Synthesis was started with ribolactone (62), which was prepared from tribenzylated ribose (61) using two methods. [33] In the first method, 62 was prepared by oxidizing protected ribose (61) 

Favipiravir (79) (called T-705, 6-fluoro-3-hydroxypyrazine-2carboxamide) is a medication that is used against influenza that acts by hindering the influenza virus's RNA-dependent RNA polymerase. [34] Favipiravir also prevents a host of other pathogenic RNA viral infections, including arenavirus, bunyavirus, flavivirus, alphavirus, and norovirus. [35, 36] Furthermore, it is considered to be a promising Ebola virus treatment candidate. [37] In the field of antiviral and antiparasitic science, favipiravir and related structures have recently received a lot of attention. [38] [39] [40] [41] [42] [43] Favipiravir is a pyrazine derivative with three substituents (CONH 2 , OH, and F) at 2, 3, and 6 positions, respectively. This compound has acidic properties due to the hydroxyl group and can be tautomerized to the keto tautomers A and B [44] (Scheme 19). (78) required treatment with the extremely corrosive Olah's reagent. [45] Given these drawbacks, this approach was not recommended for the scalable production of favipiravir (79) [46] [47] [48] The C 3-fluorine (84) is perhaps more responsive and could potentially be substituted by a hydroxyl group to produce the end product 79. [46] [47] [48] Although Scheme 21 looks inviting in terms of step count, it is not financially viable in preparing compound 3,6-dichloropyrazine-2carbonitrile (82) because of the low yield and the high cost involved in the process. Liu et al. [48] developed a one-pot synthesis of favipiravir (79) . They avoided the isolation of volatile 3,6-difluoro-2-pyrazinecarbonitrile. To obtain 83 and 84 in a one-pot form, 3,6-dichloropyrazine-2-carbonitrile (82) was treated in succession with KF and n-Bu 4 NBr in DMSO at 50°C for about 3 h and with K 2 CO 3 in DMSO, followed by aqueous hydrogen peroxide and potassium carbonate, which yielded 79 (Scheme 26).

A strategy was advanced by Nippon Soda Co. Ltd., [50] 

Pirfenidone is used to treat idiopathic pulmonary fibrosis. It works by reducing lung fibrosis by inhibiting the generation of growth factors and procollagens I and II. Following clinical trials, it was first approved in Japan for the treatment of patients with idiopathic pulmonary fibrosis. It exists in a crystalline form, designated as form A. The drug substance is filled to less than µm. [51] 3.7.1 | Synthesis of pirfenidon The synthesis begins with easily accessible 2-amino-5-methylpyridine (94) , which is diazotized in aqueous sulphuric acid with NaNO 2 to produce 2-hydroxy-5-methylpyridine (95) . The scheme is based on Adams and Schrecker's initial work in 1949 on the synthesis of 2-hydroxy-6methylpyridine. [52] Conversion of 95 into pirfenidone (96) was performed by Affiliated Medical Research Inc. in 1974, [53] wherein 5-methylpyridin-2-ol was reacted with potassium carbonate and zinc-precipitated copper sulfate in refluxing iodobenzene for 18 h at 188°C (Scheme 28).

Baricitinib, with the brand name Oluminant, is used to treat RA. Lilly, in 2020, reported in their study that baricitinib can be used to treat persons with COVID-19 due to its anti-inflammatory property. [54] The COVID-19 patients who were treated with placebo with remdesivir, baricitinib in combination with remdesivir minimized their recovery time of treatment. [55] 3.8.1 | Synthesis of baricitinib The first synthetic path to baricitinib was discovered by Rodgers et al. [56] They used tert-butyl 3-oxoazetidinel-carboxylat as the starting material, from which neopentyl 3-(cyanomethylene) azetidine-1-carboxylate (98) Later on, an improved procedure to synthesize baricitinib was developed by them by using tert-butyl 3-oxoazetidine-1-carboxylate (97) . In this scheme (Scheme 31), 3-ethylidine-1-(ethylsulphonyl) azetidine (100) was further subjected to the Horner-Emmons reaction, and instead of using t-BuOK as a base, NaH was used.

Deprotection of the N-Boc group was carried out under TFA cleavage conditions, yielding compound 99, which was then reacted with ethanesulphonyl chloride without further purification. In the presence of DBU, the nucleophilic addition between compound 100 and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-pyrazole was successfully performed. Finally, baricitinib was successfully obtained with a high yield of 49%.

Molnupiravir is an antiviral drug invented at Emorty University by its drug innovation company (Drug Innovation Ventures at Emory) for the treatment of influenza. [57, 58] Molnupiravir, also referred to as EIDD-2801, MK-4482, is under trial for the treatment of COVID-19. [59] It is an orally accessible, intravenous nucleotide product used against COVID-19 that is approved by the FDA. [60] [61] [62] [63] There are chances that it may amplify a synergic anti-SARS-CoV-19 effect along with remdesivir.

The scheme for the synthesis of molnupiravir is given below. It S C H E M E 28 Synthesis of pirfenidon By using column chromatography, Vasudevan et al. [65] published a two-step easy process of molnupiravir formation, with a total yield of 75%. Enzyme-mediated selective esterification yielded 115, followed by direct hydroxyamination, but the high cost of the procedure restricted its industrial application. They also presented an enzymefree cytidine synthetic technique that was similar to the previously reported route, besides the hydroxyamination step. This synthesis yielded a higher overall yield (44%) than the previous one (Scheme 33).

Vasudevan et al. [66] presented a more appropriate technique for the synthesis of molupiravir that started with either cytidine (114) or

Steiner et al. [67] preferred uridine (109) as the starting material and changed the procedure for introducing the N-hydroxy to this, they used a chemical process for conversion to molnupiravir, which involved in situ silylation of the product to promote product isolation and recovery. [68] The zinc-containing enzyme, cytidine deaminase (EC 3.5.4.5), catalyzes the conversion of cytidine into uridine. [69] As cytidine deaminase had previously been used on a large scale for synthesizing nonnatural nucleosides, it emerged as a promising candidate for industrial biocatalysts. [70] The proposed conversion of cytidine into N-hydroxy-cytidine catalyzed by cytidine deaminase involves the use of hydroxylamine as the nucleophile instead of water. Wild-type cytidine deaminase could hydrolyse N-hydroxycytidine to uridine, but only at a very low rate (about 2% activity compared to cytidine). On this basis, trials to convert cytidine into N-hydroxy-cytidine catalyzed by cytidine deaminase were conducted (Scheme 34).

Ribavirin (1-β-D~ribofuranosyl-l,2,4-triaz-ol-3-carboxamide) is a highly water-soluble nucleoside, initially synthesized in 1972. [71] The drug exerts antiviral actions after intracellular phosphorylation to mono, di, and especially, triphosphate nucleotide structures. [72] Because of its activity against both RNA and DNA viruses, it is extensively used for the treatment of influenzas, hepatitis B and C virus, SARS, [73] and syncytial virus. [74] There are two methods for the preparation of ribavirin: a chemical method [75] [76] [77] and an enzymatic synthesis. [78, 79] 3.10.1 | Synthesis of ribavirin A three-step production procedure is standard for a chemical protocol. 

Gemcitabine is a fluorinated nucleoside analog. [80] Originally developed by Lilly, it is an anticancer drug marketed as the HCl salt under the trade name of Gemzar (Lilly). Gemcitabine is a prodrug; it undergoes intracellular phosphorylation to its active diphosphate and triphosphate forms, which inhibit DNA synthesis leading to apoptosis. [81, 82] The drug is mainly metabolized by cytidine deaminases and almost all of it is excreted into urine as the corresponding difluorouridine species. New approaches to increase its chemotherapeutic efficiency are under investigation. [83] 3.11.1 | Synthesis of gemcitabine The first synthesis of gemcitabine was performed in the Lilly research laboratories and was published by Hertel et al. [84] in 1988 (Scheme 36).

The synthesis begins with enantiopure D-glyceraldehyde (R)-124, which is easily synthesized in two stages from D-mannitol. [85] Fluorine was introduced using a building-block method involving ethyl bromodifluoroacetate. Under typical circumstances, the Reformatsky Because fluorination at the ribose-2 position causes deactivation towards nucleobase introduction, a better anomeric leaving group was needed, such as the equivalent mesylate 129, which was produced as a 1:1 anomeric combination from lactol.

Fluvoxamine is one of several selective serotonin reuptake inhibitors used to treat depression and anxiety disorders. The effectiveness of fluvoxamine as an antidepressant is well documented. [86] Fluvoxamine has demonstrated short-term efficacy in the treatment of obsessive-compulsive disorders (OCD), panic disorder, social phobia, fluvoxamine. [87, 88] 

Rupintrivir (AG-7088, Rupinavir) is a peptidomimetic antiviral drug that acts as a 3C and 3CL protease inhibitor. [89] [90] [91] It was developed for the treatment of rhinoviruses, [92, 93] and has subsequently been investigated for the treatment of other viral diseases including those caused by picornaviruses, [94, 95] norovirus, [96] and coronaviruses, such as SARS and COVID-19. [97, 98] 3.13.1 | Synthesis of rupintivir The dianionic alkylation of N-Boc glutamic acid dimethyl ester 137 with iodoacetonitrile was the first step in this approach. As expected, this alkylation was extremely stereoselective, yielding 138 as the end product (72%). Following this, the cyano group in 138 was hydro- 

The main reason for quick spreading of COVID-19 is unavailability of proper medication. Antiviral drugs such as remdesivir or GS-441524, as well as JAK inhibitor drugs, provide an effective treatment combination to reduce mortality before a specific medicine is available. In this review, we have updated the role of many small molecules that have been shown to be effective in inhibiting COVID-19. This review presents a comprehensive account of CQ and HCQ favipiravir, remdesivir, and so forth, in terms of their biological activities, drug testing, and synthetic processes, for the preparation of these and many other potential drug candidates.

The authors thank the Vice-Chancellor and Department of Chemistry, Banasthali Vidyapith, Banasthali, India, for providing the necessary facilities for the compilation of this work.

United States patent US 2,546

US patent WO 2005062723

Proc. Natl. Acad. Sci

Synthesis of Best-Seller Drugs

European Patent Office WO 00/10569

United States patent US 8

United States Patent US 8

United States Patent US 02011003863

United States Patent US 3

COVID-19) Update: FDA Authorizes Drug Combination For Treatment of COVID-19

United States Patent US20070135461

World Patent WO1736022019

The Complete Drug Reference

The authors declare that there are no conflict of interests.

http://orcid.org/0000-0002-5764-497X Jaya Dwivedi http://orcid.org/0000-0002-1524-7714